SCHEMBL1008604

SCHEMBL1008604

CC(=O)c1ccccc1Oc1cnn(C(CC2CCCC2)C(=O)O)c(=O)c1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 1/20 0.36
METAP1 P53582 1/20 0.36
POLB P06746 1/20 0.36
SLC6A2 P23975 2/20 0.36
SLC6A4 P31645 2/20 0.36
SLC6A3 Q01959 1/20 0.36
CYP2D6 P10635 1/20 0.36
KCNH2 Q12809 1/20 0.36
F11 P03951 4/20 0.36
ABCB1 P08183 4/20 0.36
DDB1 Q16531 1/20 0.35
CRBN Q96SW2 1/20 0.35
SCN1A P35498 1/20 0.35
SCN2A Q99250 1/20 0.35
SCN3A Q9NY46 1/20 0.35
GCK P35557 1/20 0.34
TSHR P16473 2/20 0.34
MAPT P10636 1/20 0.34
NPY5R Q15761 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1008573 0.92 POLB (0.37) METAP2METAP1POLBSLC6A2SLC6A4
SCHEMBL1009403 0.88 LPAR1 (0.41) METAP2METAP1GCKNPY5R
SCHEMBL1008741 0.88 LPAR1 (0.39) METAP2METAP1F11
SCHEMBL1009230 0.88 TSHR (0.42) TSHRMAPT
SCHEMBL1007288 0.86 LPAR1 (0.41) METAP2METAP1
SCHEMBL1008265 0.86 FFAR1 (0.40) METAP2METAP1
SCHEMBL1009332 0.86 FFAR1 (0.43) METAP2METAP1KCNH2MAPTNPY5R
SCHEMBL1009307 0.86 NPY5R (0.43) METAP2METAP1NPY5R
SCHEMBL1008070 0.85 PTGDR2 (0.41) METAP2METAP1SLC6A2SLC6A4SLC6A3
SCHEMBL1008865 0.85 GCK (0.41) METAP2METAP1GCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 US disclosed
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 US disclosed
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 US disclosed
EP-2268633-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2011-01-05 EP disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed
WO-2009127544-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2009-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS GCK, GCKR, PDXK METAP2 1286/4885METAP1 1716/4885POLB 2078/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.